I became an MD in 1972, then decided to do research in biomedical sciences and received my PhD in immunology in 1978. I spent 3 years as a postdoctoral fellow at NIH, USA, then started a university carrier in Debrecen where became professor of biochemistry and molecular biology in 1988 at the Faculty of Medicine, then chairman of this department between 1993 and 2013. My research group has focused on molecular mechanisms in cell death, structure and function of transglutaminases with clinical implications, inflammation, differentiation and functions of white and brown adipocytes.
I was visiting professor at the University of Texas and the University of Rome, coordinated major European projects of COST, ESF and EU-Frame Work programs.
I was rector (1999-2001, 2007-2010) and president of the Medical and Health Science Center (2001-2007) of the University of Debrecen.
Elected to chair the Hungarian Accreditation Committee for Higher Education (2004-2007), the Hungarian Biochemical Society (2005-2015) and became a member of the Hungarian Academy of Sciences in 1998 where chaired the Science and Ethics Committee and currently chair the Biology Section of the Academy.
In 2010 I was elected to be the member of the Committee on Science and Ethics of All European Academies (ALLEA) and participated in the drafting group of the recently published new European Code of Conduct for Research Integrity. .
Since 2012 I chair the Publications Committee of the Federation of European Biochemical Societies and I am member of FEBS Executive Committee.
I have seen a nice publication in the recent issue of Science from the group of Rolf Hingenfeld who is excellent strucural biologist working in Lübeck.
Crystal Strucutre of SARC-COV-2 main protease provides a basis for design of improves alfa.ketoamide inhibitors. Science 24 April 2020 Vol 368 Issue 6489 pp 409-412 open access
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Recent Comments
Great initiative! Thanks Isabel.
I am looking forward to read the upcoming posts.
Laszlo Fesus
Dear Andrea,
Another important development.
Laszlo
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing David E. Gordon, Gwendolyn M. Jang, […]Nevan J. Krogan
https://www.nature.com/articles/s41586-020-2286-9
Dear Andrea,
I have seen a nice publication in the recent issue of Science from the group of Rolf Hingenfeld who is excellent strucural biologist working in Lübeck.
Crystal Strucutre of SARC-COV-2 main protease provides a basis for design of improves alfa.ketoamide inhibitors. Science 24 April 2020 Vol 368 Issue 6489 pp 409-412 open access